COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Remdesivir study #10 of 16
10/15 Late treatment study
SOLIDARITY Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (preprint 10/15) (Peer Reviewed)
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Source   PDF   Share   Tweet
WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50.
Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13.

SOLIDARITY et al., 10/15/2020, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 15 authors.
risk of death, 5.0% lower, RR 0.95, p = 0.53, treatment 301 of 2743 (11.0%), control 303 of 2708 (11.2%).
non-ventilated patients, 14.0% lower, RR 0.86, p = 0.13.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 16 studies
Please send us corrections, updates, or comments.
Submit